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Abstract
Collagen type IV is the major structural component of the basement membrane and COL4A1
mutations cause adult small vessel disease, familial porencephaly and HANAC syndrome. Here
we show that animals with a Col4a1 missense mutation (Col4a1+/Raw) display focal detachment of
the endothelium from the media and age dependent defects in vascular function including a
reduced response to nor-epinephrine. Age-dependent hypersensitivity to acetylcholine, is
abolished by inhibition of nitric oxide synthase (NOS) activity, indicating that Col4a1 mutations
affect vasorelaxation mediated by endothelium-derived nitric oxide (NO). These defects are
associated with a reduction in basal NOS activity and the development of heightened NO
sensitivity of the smooth muscle. The vascular function defects are physiologically relevant as
they maintain in part the hypotension in mutant animals, which is primarily associated with a
reduced red blood cell volume due to a reduction in red blood cell number, rather than defects in
kidney function. To understand the molecular mechanism underlying these vascular defects we
examined the deposition of collagen type IV in the basement membrane, and found it to be
defective. Interestingly, this mutation also leads to activation of the unfolded protein response. In
summary, our results indicate that mutations in Col4a1 result in a complex vascular phenotype
encompassing defects in maintenance of vascular tone, endothelial cell function and blood
pressure regulation.
Introduction
The basement membrane (BM) is a specialized extracellular matrix structure that
compartmentalizes tissues, provides structural support and influences cell behaviour (1).
Collagen type IV is the major structural component of the BM and in vertebrates, six
different collagen type IV alpha chains (α1(IV) - α6(IV)) have been described which
produce three different collagen type IV protomers (α1.α1.α2(IV), α3.α4.α5(IV) and
α5.α5.α6(IV) (2).
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The most abundant isoform, α1.α1.α2(IV), contributes to the formation of many basement
membranes and its deficiency causes embryonic lethality in mouse (3). COL4A1 mutations
have recently been identified as a cause of familial porencephaly, adult small vessel disease,
hemorrhagic stroke, and a new syndrome called HANAC (hereditary angiopathy with
nephropathy aneurysm and cramps) (for review see (4)). In mice deficiency in Col4a1 and
Col4a2 and missense mutations in Col4a2 lead to haemorrhaging during development (3, 5)
underscoring the important structural role of Col4a1 and Col4a2 in the vasculature.
In the vascular wall, the BM borders the vascular smooth muscle cells (VSMC) and
separates them from the endothelium, which lines the vessel lumen (1). The vascular
endothelium plays a crucial role in vasodilation through generating vasodilator agents
including nitric oxide (NO), prostaglandins I2 and E2 and endothelium-derived
hyperpolarizing factor (EDHF) (6). In large conduit vessels such as the descending aorta, the
NO-cGMP pathway predominates whereby endothelium-derived NO activates soluble
guanylate cyclase in the VSMC to generate cGMP, ultimately leading to smooth muscle
relaxation (7, 8). The resulting vasodilation can be blocked by NOS inhibitors, such as L-Nω
nitroarginine methyl ester (L-NAME). Clinically, endothelial cell dysfunction affects blood
pressure control (9, 10) and promotes atherosclerosis (11).
Recently, we have characterised an allelic series of Col4a1 mouse mutants which display a
spectrum of eye phenotypes combined with glomerulopathy (12, 13). In one of these
mutants, the Col4a1+/Raw mutation (K950E) changes a lysine residue to glutamic acid at a Y
residue of the Gly-X-Y collagen repeat in the collagen domain (12). Col4a1+/Raw animals
are characterised by retinal arteriolar silvering due to focal BM defects (12, 13). However,
the described function of Col4a1 in angiogenesis (for review see (1)), which can be
mediated through integrin signaling (14), suggests additional functional roles in the
vasculature.
To gain further insight into the role of Col4a1 in the vasculature, the vascular phenotypes of
Col4a1+/Raw mice were explored including a structural and functional analysis of
descending aortae. Mutant animals display haemorrhagic stroke and in descending aortae
focal detachment of endothelial cells from the media occurs. Mutant animals have altered
VSMC and EC function which affects the NO-cGMP pathway. Blood pressure analysis
revealed hypotension in mutant animals that is associated with a reduced blood volume and
is maintained in part by the described vasodilation defects. We also show that the
Col4a1+/Raw mutation results in defective deposition of collagen type IV in the BM of
descending aortae and leads to activation of the unfolded protein response. These results
show for the first time that defects in the basement membrane in general, and collagen type
IV in particular, affect the maintenance of vascular tone, endothelial cell function and blood
pressure regulation.
Results
Col4a1+/Raw mutation results in perinatal cerebral haemorrhages and reduced viability
Analysis of newborn Col4a1+/Raw pups revealed mild cerebral haemorrhaging in mutant
pups (Fig. 1A) with more severe haemorrhaging being observed in pups that died shortly
after birth (Fig. 1B). The perinatal cerebral haemorrhaging is associated with reduced
viability at weaning as we only detect 19.8% Col4a1+/Raw animals compared to the expected
50% (χ2 = 56.6, one degree of freedom, P<0.0001) (Fig. 1C).
Mutations in Col4a1 results in ultrastructural changes in the vessel wall
Patients with COL4A1 mutations can suffer from aneurysm formation of the carotid artery
(15) suggesting that COL4A1 mutations may affect the structure of large calibre vessels. We
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therefore performed histopathological and ultrastructural analysis on descending aortae of 6
month old Col4a1+/Raw animals which revealed no gross morphological defects and normal
total collagen and elastin deposition was observed (Fig. 1D-F, Supplemental Fig. 1).
However ultrastructurally Col4a1+/Raw mice displayed areas of focal detachment of the
intact endothelium from the underlying media (Fig. 1G and H).
Col4a1+/Raw animals have defects in vascular smooth muscle cell function
To analyse if the structural BM defects affect vascular function, myography was performed
on rings from descending aortae of 3, 6 and 11-15 month old animals. VSMC function,
assessed by contraction in response to KCl containing-physiological salt solution (K-PSS
(125mM KCl), was impaired in Col4a1+/Raw aortae (Fig. 2A; n=6, p = 0.001). This indicates
reduced contractile strength independent of endothelial function (16) and suggests that BM
defects may weaken the vessel thereby increasing the susceptibility to cerebral
haemorrhaging; observed in patients and mice with COL4A1 mutations.
Reduced contractile responses to the adrenoceptor agonist, nor-epinephrine (NE), were
observed in 6 month (Fig. 2B) and 11-15 month (Supplemental Fig. 2B) old mutant animals
(two way ANOVA p < 0.0001) but were normal in 3 month old animals (Supplemental Fig.
2A). These data would suggest that an age-dependent defect in VSMC function develops
between 3 and 6 months of age after the onset of reduced vessel wall strength.
Mutations in Col4a1 affect endothelial cell function and NO/cGMP mediated vasodilatation
Endothelial cell-mediated vasodilatation was assessed in 3, 6 and 11-15 month old animals
through the vasodilation responses to acetylcholine (ACh) on NE (EC80)-preconstricted
aortic rings. Endothelium-dependent vasorelaxation was not different between 3 month and
6 month old WT and mutant animals (Supplemental Fig. 2C, 2D). However, in contrast
aortae of 11-15 month old mutant animals displayed significantly increased vasodilatation to
ACh (two way ANOVA; p <0.0001; Fig. 2C), indicating that this age-dependent phenotype
becomes significant after 6 months. The response to ACh was mediated through the NO-
cGMP pathway as blockade of NOS activity by L-NAME abolished Ach-induced
vasodilation both in Col4a1+/Raw and WT aortic rings (Fig. 2C). Because changes in NO
generation can be accompanied by alterations in the response of the smooth muscle cells to
NO (17), aortic rings were exposed to the NO donor, sodium nitroprusside (SNP). No
differences were observed in 3 and 6 month old mutant and WT animals (Supplemental Fig.
2E, 2F). In contrast, a significant increase in SNP-induced vasodilation was observed in the
11-15 month old animals (Fig. 2D), confirming the development of increased NO sensitivity
in smooth muscle. These results show that Col4a1 mutations can affect NO-mediated
vasodilation and NO-sensitivity, suggesting an upregulation of the NO/cGMP pathway.
The observed vasodilation defects are specific to the NO-cGMP pathway as the response to
the β2 adrenoceptor agonist, isoprenaline, which induces cAMP-mediated vasodilatation
(18), was similar between WT and mutant animals (Fig. 2E). These results also indicate that
the smooth muscle of mutant vessels is able to maintain tension.
Col4a1 mutant animals have reduced basal NOS function
To further investigate the NO-cGMP pathway we assessed basal NOS function in 12 month
old aortae by measuring the constriction induced by L-NAME (19). Mutant aortae showed a
40% reduction in LNAME-induced contraction (p < 0.05) (Fig. 3A) indicating that mutant
animals have reduced basal NOS function. This reduction in activity is independent of
changes in eNOS mRNA and protein expression as shown by quantitative RT-PCR and
western blot analysis (Fig. 3C, 3D). Similarly the increased NO-sensitivity of the smooth
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muscle is independent of changes in expression of cGMP-dependent protein kinase 1 (Fig.
3B) and soluble guanylate cyclase respectively (Fig. 3D).
Collagen type IV influences vascular homeostasis
Vascular resistance is one of the key mechanisms involved in blood pressure regulation,
which can be altered through alterations in vasodilation (9) and/or vasoconstriction (20). To
investigate if the structural defects of Col4a1+/Raw animals affect vascular homeostasis, the
systolic blood pressure of 4-6 and 14 month old mice was measured by tail
plethysmography. This revealed that in both cohorts Col4a1+/Raw animals have a reduction
of 20-25 mm Hg in their systolic blood pressure (P<0.001 for both cohorts) (Fig. 4A, 4B)
indicating that mutations in collagen type IV can result in hypotension. Our results differ
from previous reports in which animals with a deletion of exon 40 in Col4a1 were
normotensive using tail plethysmography (21). It is known that different mutations in the
same collagen alpha chain can affect the displayed phenotypes and phenotype severity (12,
22). Moreover tail cuff recording of blood pressure in mice can be imprecise, particularly in
hypotensive states, and is best confirmed using direct measurement (23). We therefore
measured the blood pressure of Col4a1+/Raw animals using direct arterial cannulation. This
confirmed that the blood pressure was 20-25 mm Hg lower in mutant animals and extended
the observation to animals at 40 days of age (Fig. 4C).
The different ages of onset of the hypotension and vasodilation defects data indicate that the
vasodilation defects do not cause the hypotension. However once established the
vasodilation defects may be important for maintaining the hypotension by reducing vascular
resistance. Consequently L-NAME was administered chronically to 14 month old animals
and systolic blood pressure measurements were collected before and during treatment. Two
weeks of L-NAME treatment resulted in an increase in blood pressure in WT animals of
8.8mm Hg compared to 20.5mm Hg in mutant animals (p< 0.01) (Fig. 4D). Consequently
the treatment resulted in a partial rescue of the hypotension with systolic blood pressure of
121.9 mmHg and 113.1 mm HG for WT and mutant animals respectively. These data
confirm the hypothesis that the vasodilation defect is important for the maintenance of the
hypotension.
Hypotension in Col4a1 mutant animals is associated with a reduced blood
volume—Since the hypotension is evident before the onset of the vascular function defects,
we investigated alternative causes of low blood pressure. Given the pivotal role of the
kidney in blood pressure homeostasis (24), sodium excretion was analysed in 40 day old
animals (Fig. 5A) which showed a marked reduction in sodium clearance in mutant animals
compared to WT (P< 0.01), indicating that renal sodium wasting does not maintain the
hypotension. There was a significant increase in plasma aldosterone in mutant animals (Fig.
5B), suggesting activation of the renin-angiotensin-aldosterone system (RAAS) which
would promote sodium retention in the distal nephron.
Given the close relation between blood volume and blood pressure, we calculated the blood
volume in 40 day to 8 month old animals following measurement of plasma volume and
hematocrit. These analyses revealed a ~26% reduction in blood volume in mutant animals
(Fig. 5C, P< 0.01) which is consistent with activation of the RAAS and increased circulating
aldosterone levels. However, Col4a1+/Raw animals have normal plasma volume (Fig. 5D)
and the reduction in blood volume reflects a lower average hematocrit of 38% compared to
45% for WT animals (Fig. 5E, P < 0.001). These data indicate that the lower blood volume
is caused by a decrease in packed cell volume. The decreased packed cell volume is due to a
reduction in red blood cell number in mutant animals. Measurement of red blood cell
number (RBC) showed an 11% reduction in red blood cell number in mutant animals (Fig.
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5F, P< 0.01) as Col4a1+/Raw animals have 8.55 × 106 RBC/μl compared to 9.50 × 106 RBC/
μl for WT animals. Thus the red blood cell volume reflects a reduction in red blood cell
number.
Col4a1 mutation result in activation of the unfolded protein response—To
further characterize the molecular consequences of the Col4a1+/Raw mutation and how it
may lead to the vascular phenotypes, immunostaining was performed on descending aortae
from 12 month old animals. This revealed interrupted staining for the α1.α1.α2(IV)
network compared to continuous laminin staining, suggesting a defective deposition of
collagen type IV and altered BM composition (Fig.6A).
In the ER three collagen type IV alpha chains interact and form a collagen type IV protomer.
Mutations in proteins that affect protein folding can lead to ER stress which may lead to
activation of the unfolded protein response (UPR) (25). The presence of swollen ER vesicles
and increased expression of ER chaperones in Col4a1 mutant animals (12, 26) suggest the
occurrence of ER stress. To investigate if this occurs within the vasculature and leads to
UPR activation, quantitative RT-PCR analysis was performed to assess Bip (also known as
GRP78) mRNA expression levels, a marker for UPR activation. This revealed a 1.7 fold
increased Bip mRNA expression level in mutant animals (Fig. 6B, p < 0.05 t-test) indicative
of ER stress and UPR activation.
Discussion
The identification of COL4A1 mutations in patients with familial porencephaly (27-29) and
HANAC syndrome (15) combined with vascular phenotypes in mice (for review see (4))
underline the important structural role of type IV collagen in the vasculature. However, the
role of collagen type IV in angiogenesis implies that collagen type IV and the basement
membrane possess additional non-structural roles (1). Here we describe that a Col4a1
mutation affects vascular function and homeostasis thereby highlighting a potential novel
functional role for type IV collagen.
The Col4a1+/Raw mutation affects both the capillaries and large calibre vessels, which in
neonates results in the occurrence of cerebral haemorrhaging. Although in another Col4a1
animal model these haemorrhages can lead to the occurrence of porencephaly (28), no
evidence of porencephaly was observed in the Col4a1+/Raw animals (12). This milder
phenotype has also been observed in the eye (12) and is probably due to the less severe
effects of a mutation affecting a lysine residue at the Y position of the Gly-X-Y repeat
compared to the effects of a Gly mutation at the Gly position.
In descending aortae the mutation results in the focal separation of the endothelium from the
media. These structural defects are associated with a complex functional phenotype
affecting both VSMC and EC function. The reduced contraction in K-PSS in Col4a1+/Raw
animals indicates a reduction of contractile strength independent of endothelial function
(16). These data confirm that the structural BM defects weaken the vessel which would
increase the susceptibility to cerebral haemorrhaging observed in patients and mice with
COL4A1 mutations (15, 21, 27-31).
In addition to a reduction in contractile strength, Col4a1+/Raw animals develop a late onset
VSMC phenotype and complex EC phenotype. Basal endothelial activity is reduced as
shown by a blunted contraction in response to L-NAME (19). However stimulated NO
generation is increased as illustrated by the increased sensitivity to ACh which is abolished
by L-NAME-mediated inhibition of NOS, indicating that the mutation affects NO-mediated
vasodilation. Moreover the vessels develop an increased response to the NO donor, SNP,
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suggestive of heightened NO sensitivity of the smooth muscle. Taken together these results
suggest an up regulation of the downstream relaxative mechanism, possibly in response to
reduced basal NO production as observed in eNOS deficient animals (32, 33). Our data
suggests that the sensitisation of this pathway does not compensate the endothelial
dysfunction under basal conditions but becomes apparent upon endothelium stimulation. In
addition these results support the hypothesis that vascular smooth muscle cells have the
capacity to increase their NO sensitivity as a protective measure to counter the influence of
partially reduced endothelial function. This hypothesis is also supported by the heightened
NO sensitivity of heterozygous eNOS deficient animals (17). In eNOS deficient animals, the
increased NO sensitivity is mediated through elevated activity of soluble guanylate cyclase
(32) and cGMP-dependent protein kinase (PKG1) (33). It is likely that a similar mechanism
occurs in Col4a1+/Raw animals as no changes in expression levels were observed for sGC,
eNOS and PKG1.
The chronic administration of L-NAME and partial rescue of the hypotension indicates that
the vasodilation defects contribute to the maintenance of the low blood pressure. However,
they are unlikely to be causal as the hypotension precedes the onset of the vasodilation
defect. Renal salt wasting causes low blood pressure in several genetic disorders (for review
see (24)) but in this analysis sodium excretion was reduced in Col4a1+/Raw animals. Thus
the kidney is adapting appropriately to low blood pressure by activation the RAAS (24).
Interestingly we showed that the hypotension is associated with a reduction in blood volume
due to a decreased packed cell volume caused by a reduction in red blood cell number. The
reduced hematocrit and red blood cell number are supported by other mouse models with
Col4a1 mutations (5) although no vascular function and blood pressure regulation was
measured in these mice. These results suggest that the Col4a1 mutation is associated with
hypotension at least in part due to a reduction in blood volume and that the hypotension is
maintained at least in part by the vasodilation defect.
The mechanism underlying the reduced red blood cell number remains unknown. Because
Col4a1 mutations lead to haemorrhaging (our data and (21, 28)), chronic haemorrhaging
may underlie this phenotype. Given that no severe haemorrhaging has been observed in
mutant animals (unpublished data), this would be caused by multiple microbleeds.
Alternatively, the Col4a1 mutation may affect erythropoiesis as blood progenitor cells need
to transmigrate a basement membrane before being released into the peripheral blood and
these cells express collagen type IV degrading gelatinases (34). Thus this migration may be
affected due to mutations in type IV collagen. In addition erythroid differentiation requires
interaction with extracellular matrix proteins such as fibronectin, mediated through integrin
alpha4beta1 (35), but erythroid progenitor cells also express integrin receptors which can
bind the BM protein laminin (36). Further research is required to determine the mechanism
by which the Col4a1 mutations lead to a reduction in red blood cell number and blood
volume.
One important question is how a mutation affecting a basement membrane protein can affect
endothelial cell function and vasodilation. ER stress and UPR activation can be triggered by
mutations that affect protein folding. The triple helical domain of collagen type IV contains
numerous (> 20) interruptions which are thought to be important for its flexibility and
function given that their location within the alpha chain is highly conserved (37). The
sequences flanking the interruptions are atypical suggesting that they may play an important
role at the molecular level related to triple helix stability (38). The Col4a1+/Raw mutation
changes a lysine residue to glutamic acid at the Y position of a Gly-X-Y triplet that flanks a
major interruption (12). Although most mutation in collagen proteins affect Glycine
residues, the effects of the Col4a1+/Raw mutation combined with the inherent instability of
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the interruption may severely affect protein folding. Our data show that the Col4a1+/Raw
mutation leads to UPR activation, a coordinated response activated by and aimed at
alleviating ER stress (25). It is thus tempting to suggest that the defective deposition of
collagen type IV in the BM is an indication of reduced secretion with intracellular retention
of collagen type IV causing ER stress. This is supported by analysis of other Col4a1 mutant
mouse models that revealed intracellular retention of Col4a1, increased chaperone
expression and presence of swollen ER vesicles (12, 26, 28). UPR activation has also been
observed in response to mutations in collagen type X (39) where it results in cellular
reprogramming. Chronic ER stress is a pathologic mechanism that may lead to diseases such
as diabetes (40). Thus our data raise the interesting hypothesis that the vascular defects may
be associated with and possibly due to UPR activation. In this context it is interesting to note
that ER stress and UPR activation has been observed in endothelium in areas prone to
atherosclerosis (41), in which endothelial cell dysfunction plays an important role and is one
of the earliest markers. The identification of UPR activation due to Col4a1 mutations is also
of clinical relevance as modulation of UPR activation provides an attractive target for
intervention. Indeed, UPR activation has recently been modified successfully in a mouse
model of diabetes (40).
In conclusion, we have identified that mutations in collagen type IV are associated with
UPR activation and defects in vascular function and blood pressure regulation. As collagen
type IV is part of the basement membrane, it is tempting to speculate that other basement
membrane proteins and their receptors may have similar roles in vascular biology. In this
regard it is interesting to note that endostatin, a proteolytically cleaved fragment of collagen
XVIII (42), induces endothelium-dependent vasorelaxation (43), although the role of
collagen XVIII itself has not been investigated. Finally, it is now important to assess these
phenotypes in patients with COL4A1 mutations in order to gain a complete understanding of
the spectrum of disease phenotypes and processes affected by COL4A1 mutations.
Materials and Methods
Animals
Studies were performed under guidance from the UK Home Office. Animals were
backcrossed for 5 generations on a Bl/6 background and control animals were WT
littermates.
Ultrastructural analysis
Tissue were collected from 3 adult animals (3 and 6 months old) and processed as
previously described (12).
Histopathology
Aortae were fixed overnight in 10% neutral buffered formalin or 4% paraformaldehyde and
embedded in paraffin wax. Sections were stained with Hematoxylin-Eosin, Sirius Red or
Verhoeff stain using standard protocols (n=3).
Systolic Blood Pressure Analysis
Systolic blood pressure was measured using tail cuff plethysmography on restrained
conscious animals using an IITC model 129 analyser (Woodland Hills, CA, USA). All
animals underwent three periods of training prior to recording measurements. Per animal,
the data were generated from the average of 4 readings taken on three independent
occasions.
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In vivo studies
Mice were anesthetized with Inactin (50mg/kg IP) and prepared surgically for renal function
experiments as described (44). Mice were infused IV with isotonic saline at a rate of 200ul/
h/10g body weight. After a 40 minute equilibration period, MABP was recorded for 30-40
minutes on a Powerlab, sampling at a rate of 2Hz and urine was collected for 1 hour.
Following this, Evans Blue (1μl/g of a 0.5% solution w:v) was injected for measurement of
plasma volume: blood volume was calculated from this and hematocrit (44). At the end of
the experiment, a 500-μl blood sample was taken for measurements of aldosterone. Sodium
concentration in urine and plasma was measured by ISE (Roche). Red blood cell number
was determined using blood samples collected from the tail or cheek vein and blood counts
were performed using a coulter counter (Beckman). Statistical analysis was done by
Student’s t-test.
Myography
Aortic rings (2 mm) were prepared for myography on a wire myograph (DMT myographs,
Denmark) in PSS (NaCl, KCl, MgSO4, NaHCO3, KH2PO4, EDTA, Glucose, CaCl2),
contracted 3 times in KPSS (PSS plus 125mM KCl) and contracted in 30μM Nor-
epinephrine(NE) followed by a dilation in 1μM Acetylcholine (ACh). The following
concentration-response curves were performed: NE (10−8M – 3×10−6 M), ACh (10−9M –
3×10−6 M), SNP (10−9M – 3×10−6 M) and Isoprenaline (10−9M – 3×10−5 M). Dilation
response curves were performed following contraction (80% of maximum determined by
NE concentration-response curve) with NE. ACh concentration-response curves were
performed following incubation (15min) with 200 μM L-NAME. Basal NO levels were
determined by measuring contraction following incubation (12min) with 200μM L-NAME
after contraction with NE (30% of maximum. The amount of contraction was expressed as a
percentage of the KCl contraction. All drugs were from Sigma (Dorset, UK). Statistical
analysis was performed using Two-Way ANOVA followed by post hoc test.
RT-PCR
RNA was isolated using Tri-Reagent (Sigma, UK). First strand synthesis was performed
using AMV-RT (Roche Applied Science) and quantitative real time PCR analysis was
performed in triplicate using TaqMan Gene Expression (Applied Biosystems) assays on ABI
System 7700 (eNOS) or using Stratagene Brilliant Sybrgreen QPCR (Prkg1, Bip) on MJ
Research Chromo4 Thermal Cycler. mRNA levels were corrected using 18sRNA mRNA
levels and statistical analysis was performed using Student t-test.
Immunoblotting
Protein samples were extracted from descending aorta in the presence of RIPA buffer
containing EDTA protease (Roche Applied Science) and phosphatase inhibitors (Phostop
Roche) using standard protocols. Primary antibodies eNOS( I/1000 BD Transduction
Laboratories) and, sGC (1/2000 Sigma). Protein levels were corrected for coomassie
staining of a predominant protein band and measured using Biorad GS700 Image Analyser
software analysis. Statistical analysis was performed using unpaired t-test.
Immunohistochemistry
Cryosections were fixed for 10 minutes in acetone followed by antigen retrieval using 0.1M
HCl/KCl for 10 minutes and standard protocols. The Laminin (1/1000) antibody was a kind
gift from Dr. Ulrike Mayer and the H22 antibody against Col4a2 (1/100) from Dr.
Yoshikazu Sadu.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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NO nitric oxide
BM basement membrane
eNOS endothelial nitric oxide synthase
ACh Acetylcholine
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EDHF endothelial cell hyperpolarizing factor
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Figure 1.
Vascular phenotypes of Col4a1+/Raw mice. (A,B) Mild and more severe cerebral
haemorrhaging in Col4a1+/Raw pups (arrow). (C) Predicted (50%) and observed (19.8%)
percentage of Col4a1+/Raw animals (31/156) (black) at weaning (χ2 = 56.6, one degree of
freedom, p<0.0001). (D) Lack of gross histological phenotype in mutant aortae (E) Normal
total collagen and elastin (F) deposition in mutant animals. (Data shown for 6 month old
animals, see supplemental data for 3 and 9 month old animals). (G) Focal endothelial
detachment in aortae from Col4a1+/Raw animals (arrow). (H) Higher magnification of EM
analysis. Size 1μm (g,h), 10μm (d-f).
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Figure 2.
Assessment of vascular function. (A) Mutant animals (black bars) have reduced amounts of
contraction (mN) in K-PSS (p=0.0012 two way Anova, n=6 for 3 and 6 month old animals,
n=10 for 11-15 month old). (B) Reduced contraction to Nor-Epinephrine in 6 month old
mutant animals (n=6) (two way Anova p<0.001, 6 months). (C) 11-15 Month old mutant
animals display increased vasodilation to low concentrations of ACh (two way Anova,
n=10, p<0.0001). Incubation of vessels in LNAME (labelled +L-NAME) before
administration of ACh abolishes vasodilation. (D) Vasodilation to SNP in 11-15 month old
mutant animals shows increased relaxation (two way Anova, n=10, p<0.0001). (E)
Vasodilation to Iso-Prenaline in 11-15 month old animals (n=6). WT (open circles),
Col4a1+/Raw (filled circles). Error bars indicate standard error of measurement. * p< 0.05, **
p< 0.01, *** p<0.001 post hoc test
Van Agtmael et al. Page 13
Hum Mol Genet. Author manuscript; available in PMC 2011 October 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3.
Reduced basal NOS function in Col4a1+/Raw. (A) Contraction obtained by administration of
L-NAME as measure of amount of NO in 11-15 month animals expressed as percentage of
contraction obtained with KCl. (n= 14 WT, n=11 Col4a1+/Raw, t-test p <0.05). (B) qRT-PCR
for PRKG1 (cGMP dependant protein kinase I). Expressed as relative units to 18S RNA
levels. (n=6) (C). eNOS mRNA levels in 12 month old WT (white) and Col4a1+/Raw (black)
(n=6) 3 animals as determined by qRT-PCR relative to 18S RNA levels (p = 0.17 t-test). (D)
eNOS, and sGC protein expression levels in aortae of 11-15 month old animals.
Predominant band of coomassie gel is given as loading control (entire gel is provided in
Supplemental Fig. 3). Error bars indicate standard error of measurement. * p< 0.05 t-test.
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Figure 4.
Collagen type IV and blood pressure regulation. (A) Systolic blood pressure of 4-6 months
old animals. (Col4a1+/Raw 99 mm Hg (n=6), WT 124 mm Hg (n=5), p<0.001 t-test) (B)
Systolic blood pressure of 14 month old animals. (Col4a1+/Raw 85.1mm Hg, WT 108.1mm
Hg, n=6, p< 0.001, t-test). (C) Mean arterial blood pressure of 40 day old animals
(Col4a1+/Raw 70 mm Hg (n=5), WT 91 mm Hg (n=7), p<0.01, t-test). (D) Systolic blood
pressure of 14 month old animals before and during treatment with L-NAME.
Measurements were collected at day 0, day 7 and day 14 of treatment. (WT, n=9,
Col4a1+/Raw n=7) * p< 0.05, ** p< 0.01, *** p<0.001 t- test
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Figure 5.
Low blood pressure is associated with reduced blood volume. (A) Sodium excretion in 40
day old animals (Col4a1+/Raw 0.05 μmol/min (n=5), WT 0.2 μmol/min (n=7), p<0.05 t-test)
(B) Plasma aldosterone levels in 40 days old animals. (Col4a1+/Raw 1044 nmol/L (n=5), WT
476 nmol/L (n=7), p<0.01 t-test) (C) Blood volume in animals (Col4a1+/Raw 88.9 μl/g body
weight (n=10), WT 120 μl/g body weight (n=13), p<0.01 t-test). (D) Plasma volume of
animals. (E) Reduced hematocrit in mutant animals (Col4a1+/Raw 38% (n=15), WT 45%
(n=19), p<0.001 t-test). (F) Reduced red blood cell number in Col4a1+/Raw animals.
(Col4a1+/Raw 8.55 × 106 RBC/μl (n=10), WT 9.50 × 106 RBC/μl (n=12), p<0.01 t-test).
Error bars indicate standard error of measurement. * p< 0.05, ** p< 0.01, *** p<0.001 t- test
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Figure 6.
Col4a1+/Raw mutation results in UPR activation. (A) Interrupted staining for Col4a2 in
vascular BM of descending aortae from mutant animals in contrast to continuous laminin
(LM) staining. (arrow indicate presence of Col4a2 in BM. Arrowhead indicate absence of
Col4a2 as indicated by green staining in merged image) Size 20 μm. Detail (white square) is
provided below panel A. (B) Increased Bip mRNA expression levels in mutant animals.
Expressed as relative units to 18S RNA levels (p< 0.05 t-test, n=9).
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